
Inger Riise Bergheim
- Senior engineer; MSc; nurse
- +47 22 78 13 66
Publications 2020
Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
Acta Oncol, 59 (7), 733-740
DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
Technical Evaluation of Commercial Mutation Analysis Platforms and Reference Materials for Liquid Biopsy Profiling
Cancers (Basel), 12 (6)
DOI 10.3390/cancers12061588, PubMed 32560092
Publications 2019
A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
Transl Oncol, 12 (7), 951-958
DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
Cancer Immunol Res, 7 (5), 701-706
DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
Publications 2017
Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
ESMO Open, 2 (2), e000158
DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
Publications 2013
DNA methylation of alternative promoters directs tissue specific expression of Epac2 isoforms
PLoS One, 8 (7), e67925
DOI 10.1371/journal.pone.0067925, PubMed 23861833